Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Societal CDMO
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AD101 (Raloxifene), a 100 Series lead compound and a novel T-type calcium channel modulator demonstrated statistically significant improvement in both core symptoms of AD in Concept Trials.
Brand Name : AD101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Societal CDMO
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Societal CDMO
Deal Size : $1.0 million
Deal Type : Agreement
Details : Under terms of the new contract, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and Phase 4 clinical studies of AD101 (raloxifene).
Brand Name : AD101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 01, 2022
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Societal CDMO
Deal Size : $1.0 million
Deal Type : Agreement
Details : AD101 was initially discovered in phenotypic testing of animal models of learning and memory. It also improved learning and memory in models dependent on Aβ and tau while reducing the accumulation of both biomarkers in these animals.
Brand Name : AD101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 10, 2021
LOOKING FOR A SUPPLIER?
Reset All
